Currently out of the existing stock ratings of Andrew Fein, 19 are a HOLD (3.12%), 589 are a BUY (96.72%), 1 are a SELL (0.16%).

Andrew Fein

Work Performance Price Targets & Ratings Chart

Analyst Andrew Fein, carries an average stock price target met ratio of 32.91% that have a potential upside of 55.54% achieved within 174 days. Previously, Andrew Fein worked at HC WAINWRIGHT.

Andrew Fein’s has documented 1,188 price targets and ratings displayed on 59 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on LQDA, Liquidia Technologies at 20-Mar-2025.

Wall Street Analyst Andrew Fein

Analyst best performing recommendations are on SVRA (SAVARA).
The best stock recommendation documented was for SVRA (SAVARA) at 6/12/2019. The price target of $6 was fulfilled within 1 day with a profit of $4.57 (43.24%) receiving and performance score of 432.36.

Average potential price target upside

of $53.64 (20.99%) on BIIB (BIOGEN).
of $48.55 (20.04%) on UTHR (UNITED THERAPEUTICS).
of $36.64 (102.87%) on CRTX (CORTEXYME).

ACAD ACADIA Pharmaceuticals ANNX Annexon BIIB Biogen BLU BELLUS Health BPMC Blueprint Medicines Corp CRTX Cortexyme DBVT DBV Technologies ELOX Eloxx Pharmaceuticals EPZM Epizyme FHTX Foghorn Therapeutics IMAB I-Mab MRUS Merus BV OCUP Ocuphire Pharma PRQR ProQR Therapeutics BV SGEN Seagen AMLX Amylyx Pharmaceuticals DCPH Deciphera Pharmaceuticals LLC GMTX Gemini Therapeutics RUBY Rubius Therapeutics TARA Protara Therapeutics UTHR United Therapeutics AMRN Amarin PLC SYRS Syros Pharmaceuticals ZNTL Zentalis Pharmaceuticals Llc CPRX Catalyst Pharmaceuticals CCCC C4 Therapeutics ARVN Arvinas LQDA Liquidia Technologies ABOS Acumen Pharmaceuticals ACIU AC Immune Ltd CRBP Corbus Pharmaceuticals DNLI Denali Therapeutics FULC Fulcrum Therapeutics KALV Kalvista Pharmaceuticals MEIP MEI Pharma NBIX Neurocrine Biosciences PEPG PepGen Ltd PRTA Prothena plc PULM Pulmatrix STOK Stoke Therapeutics STRO Sutro Biopharma TCRX Tscan Therapeutics THRX Theseus Pharmaceuticals UBX Unity Biotechnology VIGL Vigil Neuroscience VRTX Vertex Pharmaceuticals WVE Wave Life Sciences Ltd ALEC Alector BCRX BioCryst Pharmaceuticals INSM Insmed KMDA Kamada KROS Keros Therapeutics KYMR Kymera Therapeutics SVRA Savara APRE Aprea Therapeutics CNCE Concert Pharmaceuticals GBT Global Blood Therapeutics DYN Dyne Therapeutics RNA Avidity Biosciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jeffrey Hung (MORGAN STANLEY)